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Compounds that can block the CXCR4 chemokine
receptor are a promising new class of antiretroviral
agents. In these experiments we studied the effect of a
modified form of the native stromal cell-derived factor-
1 (SDF-1), Met-SDF-1β. The in vitro susceptibility of
two different CXCR4-tropic HIV-1 strains was deter-
mined. Antiviral effect was assessed by the reduction of
p24 antigen production in PHA-stimulated peripheral
blood mononuclear cells with exposure to the modified
SDF-1 molecule. The 50% inhibitory concentrations
(IC50) were derived from six separate experiments. The
IC50 against the two HIV-1 isolates was in 1.0–2.8 µg/ml
range for Met-SDF-1β. Met-SDF-1β showed synergy to
additivity with either zidovudine or nelfinavir at IC75, IC90
and IC95. Additivity was seen when Met-SDF-1β was
combined with efavirenz. No cellular toxicity was
observed at the highest concentrations when these
agents were used either singly or in combination. This
compound is a promising new candidate in a receptor-
based approach to HIV-1 infection in conjunction with
currently available combination antiretroviral drug
therapies.
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CD4 T lymphocytes and macrophages are the major
targets of infection by HIV-1 [1–3]. The entry of virus
into these cells is mediated by the interaction of the
viral envelope protein gp120 with CD4 and chemokine
‘co-receptors’ [4,5]. The receptor for stromal cell-
derived factor-1 (SDF) [6,7], CXC chemokine receptor
4 (CXCR4), has been identified as the co-receptor for
T-cell-tropic strains of HIV-1 [4,8], and the CC
chemokine receptor 5 (CCR5) [9,10] is associated with
the binding and the entry of macrophage-tropic
isolates of HIV-1 [11–13]. The existence of CD4-inde-
pendent strains of HIV-1 that can enter by binding
CXCR4 [14] or CCR5 [15–17] alone suggest that these
receptors are actually the primary receptor for viral
entry, rather than ‘co-receptors’. There is also evidence
of a tendency towards CXCR4 usage later in disease
[18].
Early therapeutic attempts at blocking HIV-1
cellular entry focused on inhibition of HIV-1 attach-
ment to cellular CD4 via competition by soluble CD4
[19]. This approach resulted in effective blocking of
laboratory-adapted HIV-1 strains in vitro, but was
less effective on primary HIV-1 isolates [20] and
when tested in clinical trials [21]. The identification
of the chemokine receptors as essential factors for
HIV-1 entry has led to new therapeutic targets for
viral inhibition. The chemokines themselves, or their
variants, represent a potent and novel class of
inhibitors [22–24]. HIV-1 strains that use CCR5 are
blocked by RANTES, MIP-1α, MIP-1β and MCP-2;
viral strains that use CXCR4 are blocked by the
ligand SDF-1. These factors may work through two
independent mechanisms: (i) competitive blockage of
the interaction of gp120 with the chemokine recep-
tors; and (ii) downregulation of chemokine receptor
expression on target cells, thus limiting the possibility
of viral entry.
Stromal cell-derived factor 1α and 1β (SDF-1α and
SDF-1β: amino acids 1–67) differ by four amino acids
at the C-terminus: both bind and signal through
CXCR4 and prevent entry of T-tropic virus by
blocking its interaction with gp120. In this study we
have examined the activity of a modified form of the
native SDF-1β in which an N-terminus methionine
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residue was added (Met-SDF-1β) [25]. Met-SDF-1β
was tested alone and in combination with other anti-
retroviral drugs.
Materials and Methods
Viruses
The two viruses used for these experiments were HIV-
1 IIIB (a syncytium-inducing prototypic strain from RC
Gallo) and 14a-Pre (a clinical isolate) [26]. 14a-Pre was
derived from an HIV-1-seropositive individual before
antiretroviral therapy and was wild-type at reverse
transcriptase codons 41, 67, 70, 215 and 219. Virus
stocks were prepared according to the method
described by Johnson et al. [26] in peripheral blood
mononuclear cells (PBMCs) obtained according to
standard isolation techniques [AIDS Clinical Trials
Group (ACTG) Virology Manual]. Cell-free super-
natant fluids were harvested twice a week for HIV-1
p24 antigen production assay (NEN Research
Products, Boston, Mass., USA), and cell-free super-
natants containing breakthrough viruses were tested
for syncytium-inducing (SI) capacity using the ACTG
protocol for detection of SI isolates [27]. Viral titration
was carried out in PBMCs and the viral titre, measured
as TCID50/ml, was calculated by the method of Reed
and Muench [28].
Three CCR5-tropic viruses were used as a control
and included Ba-L (a prototypic strain from RC Gallo),
RM and MB; the latter two were described previously
[29] and were derived from patients with primary HIV-
1 syndromes (PHI). Cellular tropism of those viruses
was tested on U87MG-CD4 lymphocytes (a gift from
Dan Littman, New York University School of
Medicine, N.Y., USA).
Compounds
Met-SDF-1β (lot no. 4488–208) was provided at a
concentration of 0.32 mg/ml and had the sequence
MKPV at the amino terminus [25] and was dissolved
in Tris buffer (provided by Genetics Institute,
Cambridge, Mass., USA).
Zidovudine was obtained from the Wellcome
Research Laboratories (Beckenham, UK). It was
dissolved in sterile PBS and stored at a concentration of
4 mM. Nelfinavir was obtained from Agouron
Pharmaceuticals (La Jolla, Calif., USA), dissolved in
DMSO, and stored at a concentration of 10 mM.
Efavirenz was obtained from DuPont Pharmaceuticals
(Wilmington, Del., USA), dissolved in PBS, and stored
at a concentration of 10 mM.
Drug susceptibility test
The in vitro susceptibility of two different CXCR4
HIV-1 strains was determined in PBMCs. Fixed
amounts of infectious virus (1000 TCID50) with a
multiplicity of infection of 0.01 TCID50/cell were used
to infect PHA-P-stimulated PBMCs that were either
drug-free (control wells) or pretreated with four Met-
SDF-1β concentrations each in duplicate wells.
Met-SDF-1β was used at concentrations ranging from
0.35 to 2.80 µg/ml in experiments with 14a-Pre and
from 0.875 to 7 µg/ml in experiments with IIIB. Met-
SDF-1β was added to the culture, either simultaneously
with virus, or 1 h prior to virus addition. Antiviral
effect was assessed by reduction of p24 antigen
production in PHA-stimulated PBMCs after harvesting
of the cell-free supernatant fluids on days 4, 7 and 11.
The IC50 values were derived from three separate
experiments, and were expressed as mean± standard
error of the mean (SEM). The effects of Met-SDF-1β on
cell viability were assessed on uninfected cultures
maintained in parallel using the trypan blue dye exclu-
sion method.
In a second set of experiments, we studied combina-
tions of Met-SDF-1β with several other antiretroviral
compounds, including zidovudine, nelfinavir and
efavirenz. Diluted fixed-ratio combinations of the
drugs were added to each well in duplicate.
Combination drug assays were performed with the
following concentrations of each drug: 0.5×IC50, IC50,
2×IC50 and 4×IC50. Each combination experiment was
conducted three times.
Mathematical analysis of single-agent inhibitory
concentration
At different time-points the IC50 values for each viral
isolate was determined by the dose–effect analysis
[30,31] as described previously [26] using the Systat
computer software program for Macintosh, version
5.1 (Evanston, Ill., USA).
Evaluation of the interaction between Met-SDF-1β
and the different compounds
The multiple dose–effect equation of Chou and
Talalay, based on the median-dose–effect principle and
the isobologram technique, was used to analyse
combined drug effects. The method involves plotting
dose–response curves for each agent and for fixed-ratio
combinations of the agents as previously described
[32]. Drug interactions were determined by the
median-dose–effect analysis with the combination
index (CI) calculated at several efficacy doses (IC50–95)
[32]. Mean CI values were determined as well as SEM.
In this study, we defined a combination as synergistic if
the CI was <1, greater then the expected additive effect
when two agents are combined, additive if the value
was between 1 and 1.2, and antagonistic if the value is
>1.2, less than the expected additive effect when two
agents are combined.
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Results
Both virus isolates demonstrated susceptibility to Met-
SDF-1β. Met-SDF-1β inhibited CXCR4-tropic HIV-1
isolates at concentrations lower than 3 µg/ml. Met-SDF-
1β IC50 mean±SEM was 1.040±0.180 µg/ml with IIIB
and 2.850±1.030 µg/ml with 14a-Pre infections.
Dose–response curves are shown in Figure 1. No differ-
ences were noted between pre-incubation and
simultaneous administration of Met-SDF-1β, and a
dose-related response was observed against both viruses.
No cellular toxicity appeared at the highest concentra-
tions used for the entire duration of the experiments.
Controls for the specificity of these compounds
included CCR5-tropic viruses (Ba-L and the PHI isolates
RM and MB). No activity was seen using a broad range
of drug concentrations against these viruses (data not
shown).
In the second part of the experiments Met-SDF-1β
was evaluated in combination with other antiretrovirals.
The CIs (mean±SEM) for both CXCR4 viruses are
shown in Table 1, assuming mutually exclusive effects.
Met-SDF-1β showed synergy to additivity with either
zidovudine or nelfinavir at IC75, IC90 and IC95 against
both viruses.
Against both isolates, Met-SDF-1β demonstrated an
additive effect in combination with zidovudine, nelfi-
navir and efavirenz at IC50, with CI values ranging from
1.021 to 1.202 (Table 1). Additivity (CIs 1–1.2) was also
seen when Met-SDF-1β was combined with efavirenz at
other concentrations (IC75, IC90 and IC95). No cellular
toxicity was observed when these agents were used in
combination, even at the highest concentrations used.
Zidovudine, nelfinavir and efavirenz were maintained
as single-target controls in all experiments. IC50 values
were as follows: zidovudine 0.0053±0.0028 µM, nelfi-
navir 0.0491±0.0215 µM and efavirenz 0.0027±0.0017
µM.
Discussion
The α-chemokine SDF and its derivatives, such as Met-
SDF-1β, interfere with the fusion and entry of
CXCR4-tropic HIV-1 strains into target cells by
binding to the CXCR4 receptor [6,7]. Down-modula-
tion of chemokine receptors is likely to be required for
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HIV-1 inhibition by Met-SDF-1β combinations
14a-Pre/PBMC
Combination Index values at
IC50 IC75 IC90 IC95
MetSDF-1β + zidovudine 1.021±0.316 0.836±0.174 0.690±0.134 0.632±0.114
MetSDF-1β + nelfinavir 1.202±0.116 1.037±0.074 0.921±0.048 0.862±0.039
MetSDF-1β + efavirenz 1.150±0.034 1.257±0.060 1.190±0.070 1.153±0.072
Table 1. Combination index values
IIIB/PBMC
Combination Index values
IC50 IC75 IC90 IC95
MetSDF-1β+zidovudine 1.104±0.186 0.560±0.449 0.590±0.273 0.755±0.039
MetSDF-1β+nelfinavir 1.097±0.891 0.942±0.016 0.671±0.343 0.610±0.444
MetSDF-1β+efavirenz 1.077±0.171 1.011±0.061 1.055±0.019 1.080±0.068
p2
4 
Ag
 (n
g/
m
l)
0
100
90
80
70
60
50
40
30
20
10
0.35 0.70 1.40 2.80
III B
Met-SDF-1β (ng/ml)
120
100
80
60
40
20
0
0.875 1.75 3.5 7
Met-SDF-1β (ng/ml)
14a Pre
p2
4 
Ag
 (n
g/
m
l)
Figure 1. Dose–response curves of Met-SDF-1β in HIV-1 infections
efficient inhibition of HIV-1 [25,34], and Met-SDF-1β
shown to cause prolonged down-modulation of its
receptor CXCR4 [25]. The modified form of SDF-1,
for example, Met-SDF-1β, more efficiently inhibited
CXCR4-tropic HIV-1 strains than the wild-type SDF-
1β (human SDF1β inhibited viral replication 1–3 log10
less than Met-SDF-1β). We have verified the tropism of
the two isolates examined in this study on U87MG-
CXCR4-transfected cells. The replication profile
confirmed the lymphotropic nature of these isolates, in
contrast to Ba-L, RM and MB, which replicated in
CCR5-transfected cells.
The agent evaluated in this study, Met-SDF-1β, was
tested as a single agent and was also examined in
combination with other antiretroviral agents. Met-
SDF-1β inhibits CXCR4 HIV-1 infections, either as a
single agent or as part of a combination regimen.
Synergistic effects were observed in dual treatments
with zidovudine or nelfinavir at drug concentrations
greater than IC75. In our study, we found that the CIs
between the two compounds of the combination
decreased at higher inhibitory concentrations, with the
exception of efavirenz, which demonstrated a stable
additive effect at various inhibitory concentrations
when combined with Met-SDF-1β. Of interest, prelim-
inary studies suggest that Met-SDF-Fc, a new
derivative of SDF-1α (Genetics Institute), may be active
in inhibiting CXCR4 HIV-1 isolates at even lower
concentrations (IC50 <0.5 µg/ml).
Other CXCR4-acting agents have been considered
as antiviral agents. In contrast to Met-SDF-1β, which
induces enhanced calcium flux through CXCR4 [25],
other peptide [34,35] and small molecule [36,37]
antagonists of CXCR4 have been found to inhibit 
HIV-1 replication without signalling through CXCR4.
Overall, SDF-1 derivatives have shown a good thera-
peutic index as single agents and in combination
regimens in vitro. This is particularly important when
considering that disease progression is usually associ-
ated with a shift in chemokine receptor usage, from
CCR5 to CXCR4 [18].
Current therapies approved for HIV-1 infection
inhibit the two viral enzymes reverse transcriptase and
protease. Although currently available combination
regimens have shown a potent antiretroviral activity,
many HIV-1-infected individuals develop virological
failure over time because of incomplete viral suppres-
sion and the emergence of drug resistance. Thus, the
development of new classes of compounds with a
different mechanism of action is an important research
objective in order to minimize the development of
resistance.
Newer orally bioavailable inhibitors directed to X4
viruses are needed focusing the attention for the devel-
opment of small molecules, such as AMD3100
[37–39]. Of interest, the HIV-1 (gp41) attachment/
entry to the cell membrane as new site of attack has
been recently reported with agents such as T-20 [40]
and T1249 [41], and more recently by Kim et al. [42]
and Harrison et al. [43]. Our study points out the like-
lihood that Met-SDF-1β will need to be used in
combination with either: (a) existing antiretrovirals; or
(b) other cell-membrane active agents.
To our knowledge this is the first experimental work
dealing with in vitro combinations of entry/fusion
blockers and enzymatic HIV-1 inhibitors. Our results
suggest that Met-SDF-1β may be a candidate for devel-
opment of a receptor-based approach to HIV-1
infection, most likely in combination with other potent
antiretroviral drugs. However, it is only through care-
fully designed and conducted therapeutic trials that the
clinical validity of these in vitro studies can be deter-
mined.
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